LETICIA KHOSAMA: Open Payments
NPI 1063768737 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,080 in 31 payments from 16 companies in 2025. Trend: 2023 $3,110 · 2024 $1,540 · 2025 $1,080
Food & beverage: $705Long term medical supply or device loan: $199Education: $176
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | $280 |
| Janssen Biotech, Inc. | 2 | $101 |
| E.R. Squibb & Sons, L.L.C. | 2 | $100 |
| Incyte Corporation | 4 | $97 |
| Daiichi Sankyo Inc. | 1 | $96 |
| Lilly USA, LLC | 3 | $75 |
| Stemline Therapeutics Inc. | 3 | $67 |
| Merck Sharp & Dohme LLC | 2 | $62 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $45 |
| AstraZeneca Pharmaceuticals LP | 1 | $31 |
Products named: KISQALI, ENHERTU, ERLEADA, VERZENIO, MONJUVI, Orserdu, KEYTRUDA, Nubeqa.
Industry payments across TX — which companies pay providers there.
